USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY
The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufa...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HILL, PRUDENCE ANN NIKOLIC-PATERSON, DAVID JOHN ATKINS, ROBERT CHARLES KELLY, DARREN JAMES CHADBAN, STEVEN JAMES GILBERT, RICHARD ERNEST COOPER, MARK EMMANUEL |
| description | The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or I gA nephropathy. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2401812C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2401812C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2401812C3</originalsourceid><addsrcrecordid>eNqFi7EKwjAQQLM4iPoN3g8Itjq4XtOLOcQkJOeQqRSJk2ih_j-24O70hvfeUuVbIvAGQns2EElTEB9BcvSJHcGFHU4BO8sNTyaBmbUlkEgoV3Iy3y1jQ8IaHAUbfUCxea0Wj_45ls2PK7U1JNruyvDuyjj09_Iqn05jfdxXp6rWh__FF2EKMJw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY</title><source>esp@cenet</source><creator>HILL, PRUDENCE ANN ; NIKOLIC-PATERSON, DAVID JOHN ; ATKINS, ROBERT CHARLES ; KELLY, DARREN JAMES ; CHADBAN, STEVEN JAMES ; GILBERT, RICHARD ERNEST ; COOPER, MARK EMMANUEL</creator><creatorcontrib>HILL, PRUDENCE ANN ; NIKOLIC-PATERSON, DAVID JOHN ; ATKINS, ROBERT CHARLES ; KELLY, DARREN JAMES ; CHADBAN, STEVEN JAMES ; GILBERT, RICHARD ERNEST ; COOPER, MARK EMMANUEL</creatorcontrib><description>The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or I gA nephropathy.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090609&DB=EPODOC&CC=CA&NR=2401812C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090609&DB=EPODOC&CC=CA&NR=2401812C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HILL, PRUDENCE ANN</creatorcontrib><creatorcontrib>NIKOLIC-PATERSON, DAVID JOHN</creatorcontrib><creatorcontrib>ATKINS, ROBERT CHARLES</creatorcontrib><creatorcontrib>KELLY, DARREN JAMES</creatorcontrib><creatorcontrib>CHADBAN, STEVEN JAMES</creatorcontrib><creatorcontrib>GILBERT, RICHARD ERNEST</creatorcontrib><creatorcontrib>COOPER, MARK EMMANUEL</creatorcontrib><title>USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY</title><description>The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or I gA nephropathy.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFi7EKwjAQQLM4iPoN3g8Itjq4XtOLOcQkJOeQqRSJk2ih_j-24O70hvfeUuVbIvAGQns2EElTEB9BcvSJHcGFHU4BO8sNTyaBmbUlkEgoV3Iy3y1jQ8IaHAUbfUCxea0Wj_45ls2PK7U1JNruyvDuyjj09_Iqn05jfdxXp6rWh__FF2EKMJw</recordid><startdate>20090609</startdate><enddate>20090609</enddate><creator>HILL, PRUDENCE ANN</creator><creator>NIKOLIC-PATERSON, DAVID JOHN</creator><creator>ATKINS, ROBERT CHARLES</creator><creator>KELLY, DARREN JAMES</creator><creator>CHADBAN, STEVEN JAMES</creator><creator>GILBERT, RICHARD ERNEST</creator><creator>COOPER, MARK EMMANUEL</creator><scope>EVB</scope></search><sort><creationdate>20090609</creationdate><title>USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY</title><author>HILL, PRUDENCE ANN ; NIKOLIC-PATERSON, DAVID JOHN ; ATKINS, ROBERT CHARLES ; KELLY, DARREN JAMES ; CHADBAN, STEVEN JAMES ; GILBERT, RICHARD ERNEST ; COOPER, MARK EMMANUEL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2401812C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2009</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HILL, PRUDENCE ANN</creatorcontrib><creatorcontrib>NIKOLIC-PATERSON, DAVID JOHN</creatorcontrib><creatorcontrib>ATKINS, ROBERT CHARLES</creatorcontrib><creatorcontrib>KELLY, DARREN JAMES</creatorcontrib><creatorcontrib>CHADBAN, STEVEN JAMES</creatorcontrib><creatorcontrib>GILBERT, RICHARD ERNEST</creatorcontrib><creatorcontrib>COOPER, MARK EMMANUEL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HILL, PRUDENCE ANN</au><au>NIKOLIC-PATERSON, DAVID JOHN</au><au>ATKINS, ROBERT CHARLES</au><au>KELLY, DARREN JAMES</au><au>CHADBAN, STEVEN JAMES</au><au>GILBERT, RICHARD ERNEST</au><au>COOPER, MARK EMMANUEL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY</title><date>2009-06-09</date><risdate>2009</risdate><abstract>The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or I gA nephropathy.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2401812C |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T11%3A41%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HILL,%20PRUDENCE%20ANN&rft.date=2009-06-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2401812C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |